Luminex, Merck to develop companion Dx for Alzheimer's drug

03/14/2013 | GenomeWeb Daily News (free registration) · Fox Business

Luminex and Merck & Co. have entered a partnership to develop a companion test for the latter's MK-8931, an investigational drug for Alzheimer's disease. The test will be used to screen patients for a clinical trial of MK-8931. The assay will assess levels of two potential disease biomarkers in cerebrospinal fluid samples from patients who demonstrate mild cognitive impairment.

View Full Article in:

GenomeWeb Daily News (free registration) · Fox Business

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY